Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug for resisting Coxsackie virus and preparing method and application thereof

A coxsackie virus and drug technology, applied in the direction of antiviral agents, pharmaceutical formulas, medical preparations containing active ingredients, etc., to achieve the effect of no toxic side effects, simple preparation method, and remarkable effect

Active Publication Date: 2015-09-16
海南制药厂有限公司
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In the prior art, Amethyst nudiflora and Casuarina are commonly used for inflammation caused by bacterial infection, but there is still a lot of room for research on the inhibition of viruses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for resisting Coxsackie virus and preparing method and application thereof
  • Drug for resisting Coxsackie virus and preparing method and application thereof
  • Drug for resisting Coxsackie virus and preparing method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Preparation of Auranthus nudiflora extract (Aurora nudiflora dry extract):

[0036] The above-mentioned extract of Auranthus nudica is preferably prepared by the following method: take Auranthus nudica, cut into 1-2cm slices, add 10 times the amount of 90% ethanol, reflux extraction twice, the first time for 2 hours, the second Filtrate for 1 hour, recover ethanol from the filtrate and concentrate to a thick paste with a relative density of 1.30-1.33 (70-80°C), dry it under reduced pressure at 70-80°C, and grind it into a fine powder for later use; add 8 times the dregs respectively, 6 times the amount of water, decoct twice for 1 hour each time, filter, combine the filtrates, concentrate to a clear paste with a relative density of 1.19-1.21 (50-60°C), spray dry, combine with the above ethanol extract, and mix well , crushed and passed through an 80-mesh sieve for later use.

[0037] Preparation of casuarina extract (casuarina dry extract):

[0038] The casuarina extr...

Embodiment 2

[0040] drug toxicity test

[0041] Resuscitate the cells to be tested and pave a 96-well plate with a cell density of 1*10 5 pieces / ml. After the cells grow into a monolayer, the drug to be tested is diluted to 8 concentrations (6-7 concentrations are also acceptable, that is, 10 6 -10 8), added to a 96-well plate, 100 μl per well, 6 replicate wells were set up, and a normal cell control was set at the same time. Observe under the microscope every day, and determine the maximum non-toxic concentration of the drug according to the cell morphology (compared with the normal cell group). The general state of cytotoxicity is that the cells become round and fall off. At the end of the culture (after 48 or 72 hours), 10ul / well of MTT solution (thiazolan solution) was added, and the culture was continued for 4h. Carefully aspirate MTT, add DMSO (dimethyl sulfoxide) 100ul / well, shake and incubate for 15min (be careful to avoid light during this process), after the microplate reade...

Embodiment 3

[0044] Antiviral experiment of anti-coxsackie virus drugs

[0045] After the Hela cells grow to the logarithmic phase, they are infected with the virus, and then drug solutions of different concentrations are added (doubling dilution from the maximum non-toxic concentration), and cultured in an incubator. The experiment was divided into five treatment groups:

[0046]

[0047] As described in the present invention, in above experiment, the configuration method of drug solution is as follows:

[0048] 1) Treatment groups 1 and 2

[0049] Take 300ug / mL MMH as an example: take 300ug of MMH dry extract powder (prepared in Example 1) and dissolve it in 1mL of pure water to obtain a 300ug / mL MMH solution. Other concentration 0-300 (ug / mL) group solutions are obtained by diluting the corresponding multiples with this high concentration group solution with water.

[0050] 2) Treatment group 3-5

[0051] Take 25% MMH:75% LH (1:3) as an example: its high concentration group (300u...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug for resisting the Coxsackie virus and the preparing method and application thereof. The drug can resist the Coxsackie virus, has a remarkable effect, and is free of toxic and side effects, easy to produce and broad in market development prospect. Specifically, the drug combination for resisting the Coxsackie virus has a synergistic interaction effect after optimization, and the antiviral effect is far better than that of single callicarpa nudiflora or horsetail beefwood.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicine, and in particular relates to an anti-Coxsackie virus medicine, a preparation method and application thereof. Background technique [0002] Coxsackie virus (Coxsachie virus) is a kind of enterovirus (Enteroviruses) of picornaviridae, can be divided into A and B two kinds. Modern medicine has confirmed that Coxsackie virus is closely related to many diseases, such as pancreatitis, myocarditis, myocardial failure and dilated cardiomyopathy. Among them, Coxsackie CVB3 virus, Coxsackie virus group B virus infection type 3 (CVB3), is a common and typical cytolytic virus, and is also the main pathogenic factor of viral myocarditis. Although new antiviral drugs have been emerging this year, there is no ideal chemical drug for CVB3. Although ribavirin can inhibit CVB3 virus to a certain extent, it is difficult to implement due to its large toxic and side effects. [0003] Callicarpa Nudiflora...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/85A61K36/185A61P31/14
Inventor 蒲含林李秀峰赖潜李武
Owner 海南制药厂有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com